References
- RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
- ANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology20091161576519118696
- BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology20131201046105623352196
- DvorakHFVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin Oncol2002204368438012409337
- PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumabAngiogenesis20121517118522302382
- RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci2003443186319312824270
- StewartMWWhat are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical modelEye Rep20111.1e5
- CATT Research GroupMartinDFMaguireMGRanibizumab and Bevacizumab for neovascular age-related macular degenerationN Engl J Med20113641897190821526923
- MartinDFMaguireMGFineSLComparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research GroupRanibizumab and bevacizumab for neovascular age-related macular degeneration: two-year resultsOphthalmology20121191388139822555112
- RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multi-center cohort study (SEVEN-UP)Ophthalmology20131201823283185
- SilvaRAxer-SiegelREldemBSECURE Study GroupThe SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degenerationOphthalmology201312013013923021093
- SingerMAAwhCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology20121191175118322306121
- SinghRPSrivastavaSEhlersJPBediRSchachatAPKaiserPKA single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysisBr J Ophthalmol201498suppl 1i22i2724836866
- Eylea [package insert]Tarrytown, NYRegeneron Pharmaceuticals, Inc2011 Available from: http://www.regeneron.com/Eylea/eylea-fpi.pdf
- BeckRWMokePSTurpinAHA computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocolAm J Ophthalmol2003135219420512566024
- ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol2013014
- BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degenerationAm J Ophthalmol2013156152223706500
- HoVYYehSOlsenTWShort-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitorsAm J Ophthalmol2013156232823664153
- YonekawaYAndreoliCMillerJBConversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degenerationAm J Ophthalmol2013156293523668679
- StewartMWRosenfeldPJPredicted biological activity of intravitreal VEGF TrapBr J Ophthalmol200892566766818356264
- HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology20121192537254823084240